Payment overview · 2025
General Payments
$446.64
7 reported records · 4 companies
Healthcare provider profile · identity verified
Luna Chen, DO
Allopathic & Osteopathic Physicians|Internal Medicine · ELIZABETH, PA · NPI 1942798525
Verified facts
What the public records show
CMS Open Payments records show Luna Chen, DO received $446.64 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 63.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $281.97 | 63.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 28.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.00 | 5.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.67 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $446.64 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
172 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 514 | 162 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 278 | 80 |
| Lisinopril | Lisinopril | 251 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 188 | 53 |
| Gabapentin | Gabapentin | 181 | 46 |
| Losartan Potassium | Losartan Potassium | 175 | 51 |
| Eliquis | Apixaban | 172 | 39 |
| Omeprazole | Omeprazole | 147 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 36 |
| Ozempic | Semaglutide | 138 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 52 |
| Metformin Hcl | Metformin Hcl | 121 | 42 |
| Glipizide Er | Glipizide | 119 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 35 |
| Metformin Hcl Er | Metformin Hcl | 118 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 28 |
| Carvedilol | Carvedilol | 107 | 24 |
| Sertraline Hcl | Sertraline Hcl | 106 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 44 |
| Trazodone Hcl | Trazodone Hcl | 104 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 27 |
| Alendronate Sodium | Alendronate Sodium | 89 | 34 |
| Famotidine | Famotidine | 87 | 28 |
| Montelukast Sodium | Montelukast Sodium | 81 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 16 |
| Furosemide | Furosemide | 79 | 36 |
| Simvastatin | Simvastatin | 75 | 22 |
| Prednisone | Prednisone | 74 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 20 |
| Atenolol | Atenolol | 66 | 19 |
| Alprazolam | Alprazolam | 64 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 45 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 14 |
| Azithromycin | Azithromycin | 50 | 41 |
| Jardiance | Empagliflozin | 50 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 20 |
| Tramadol Hcl | Tramadol Hcl | 50 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Meloxicam | Meloxicam | 44 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 41 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 35 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | 17 |
| Finasteride | Finasteride | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 12 |
| Ezetimibe | Ezetimibe | 37 | 15 |
| Allopurinol | Allopurinol | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | 12 |
| Methylprednisolone | Methylprednisolone | 33 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 13 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 15 |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Etodolac | Etodolac | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | 11 |
| Naproxen | Naproxen | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Glipizide | Glipizide | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Rybelsus | Semaglutide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $446.64 · 7 records | Novo Nordisk Inc | Cologuard Collection Kit, NURTEC ODT, Ozempic, REPATHA, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error